Breast cancer expression profiling: the impact of microarray testing on clinical decision making

Bibliography

• Primary Therapy of Early Breast Cancer, 9th International Conference. January 26-29 2005, St Gallen, Switzerland. Breast (2005) 14(Suppl. 1):S1-56.
   PubMed Web of Science ®Google Scholar
• EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP (EBCTCG): Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet (1998) 351:1451-1467.
   PubMed Web of Science ®Google Scholar
• BAST RC Jr, RAVDIN P, HAYES DF et al.: American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. (2001) 19(6):1865-1878.
   PubMed Web of Science ®Google Scholar
• PAIK S, SHAK S, TANG G et al.: Multi-gene RT-PCR assay for predicting recurrence in node-negative breast cancer patients – NSABP studies B-20 and B-14. Breast Cancer Res Treat. (2003) 82:A16. Abstract.
   Google Scholar
• PAIK S, SHAK S, TANG G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. (2004) 351(27):2817-2826.
   PubMed Web of Science ®Google Scholar
• VAN ‘T VEER LJ, DAI H, VAN DE VIJVER MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 415(6871):530-536.
   PubMed Web of Science ®Google Scholar
• VAN DE VIJVER MJ, HE YD, VAN’T VEER LJ, DAI H et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347(25):1999-2009.
   PubMed Web of Science ®Google Scholar
• WANG Y, KLIJN JG, ZHANG Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 365(9460):671-679.
   PubMed Web of Science ®Google Scholar
• NOVAK JP, KIM SY, XU J et al.: Generalization of DNA microarray dispersion properties: microarray equivalent of t-distribution. BMC Biology Direct (2006) 1:27.
   PubMed Web of Science ®Google Scholar
• PICCART MJ, LOI S, VAN’T VEER LJ et al.: Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? Breast Cancer Res. Treat. (2004) 88:S17. Abstract 38.
   PubMed Web of Science ®Google Scholar
• PEROU CM, SORLIE T, EISEN MB et al.: Molecular portraits of human breast tumours. Nature (2000) 406(6797):747-752.
   PubMed Web of Science ®Google Scholar
• SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001) 98(19):10869-10874.
   PubMed Web of Science ®Google Scholar
• SOTIRIOU C, NEO SY, MCSHANE LM et al.: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA (2003) 100(18):10393-10398.
   PubMed Web of Science ®Google Scholar
• SORLIE T, TIBSHIRANI R, PARKER J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA (2003) 100(14):8418-8423.
   PubMed Web of Science ®Google Scholar
• MARTIN KJ, KRITZMAN BM, PRICE LM et al.: Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. (2000) 60(8):2232-2238.
   PubMed Web of Science ®Google Scholar
• SOTIRIOU C, WIRAPATI P, LOI S et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. (2006) 98(4):262-272.
   PubMed Web of Science ®Google Scholar
• SORLIE T: Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer (2004) 40(18):2667-2675.
   PubMed Web of Science ®Google Scholar
• WILSON KS, ROBERTS H, LEEK R, HARRIS AL, GERADTS J: Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. (2002) 161(4):1171-1185.
   PubMed Web of Science ®Google Scholar
• YU K, LEE CH, TAN PH, TAN P: Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin. Cancer Res. (2004) 10(16):5508-5517.
   PubMed Web of Science ®Google Scholar
• ROUZIER R, PEROU CM, SYMMANS WF et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. (2005) 11(16):5678-5685.
   PubMed Web of Science ®Google Scholar
• OH DS, TROESTER MA, USARY J et al.: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. (2006) 24(11):1656-1664.
   PubMed Web of Science ®Google Scholar
• ZHAO H, LANGEROD A, JI Y et al.: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell (2004) 15(6):2523-2536.
   PubMed Web of Science ®Google Scholar
• WANG Y, SORLIE T, XIAO C et al.: Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey microarrays. Breast Cancer Res. (2005) 7(Suppl. 2):P4.27.
   Google Scholar
• BRENTON JD, CAREY LA, AHMED AA, CALDAS C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol. (2005) 23(29):7350-7360.
   PubMed Web of Science ®Google Scholar
• PAWITAN Y, BJOHLE J, AMLER L: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. (2005) 7(6):R953-R964.
   PubMed Web of Science ®Google Scholar
• SHEN R, GHOSH D, CHINNAIYAN AM: Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics (2004) 5(1):94.
   PubMed Web of Science ®Google Scholar
• REIS-FILHO JS, WESTBURY C, PIERGA JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol. (2006) 59(3):225-231.
   PubMed Web of Science ®Google Scholar
• LOI S, SOTIRIOU C, BUYSE M et al.: Molecular forecasting of breast cancer: time to move forward with clinical testing. J. Clin. Oncol. (2006) 24(4):721-722.
   PubMed Web of Science ®Google Scholar
• HU Z, FAN C, OH DS, MARRON JS et al.: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 7(1):96.
   PubMed Web of Science ®Google Scholar
• WARNAT P, EILS R, BRORS B: Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics (2005) 6:265.
   PubMed Web of Science ®Google Scholar
• SIMON R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. (2005) 23(29):7332-7341.
   PubMed Web of Science ®Google Scholar
• SIMON R: Development and validation of therapeutically relevant multi-gene biomarker classifiers. J. Natl. Cancer Inst. (2005) 97(12):866-867.
   PubMed Web of Science ®Google Scholar
• SIMON R: Using DNA microarrays for diagnostic and prognostic prediction. Expert Rev. Mol. Diagn. (2003) 3(5):587-595.
   PubMed Web of Science ®Google Scholar
• BRENTON JD, AHMED AA, CALDAS C: In reply. J. Clin. Oncol. (2006) 24:722-723.
   Web of Science ®Google Scholar
• NG JK, LIU WT: Miniaturized platforms for the detection of single-nucleotide polymorphisms. Anal. Bioanal. Chem. (2006). In press.
   Google Scholar
• HUANG J, WEI W, ZHANG J et al.: Whole genome DANN copy number changes identified by nigh density oligonucleotide arrays. Hum. Genomics (2004) 1(4):287-299.
   PubMedGoogle Scholar
• SCHUBERT EL, HSU L, COUSENS LA et al.: Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am. J. Pathol. (2002) 160(1):73-79.
   PubMed Web of Science ®Google Scholar
• EDEN P, RITZ C, ROSE C, FERNO M, PETERSON C: ‘Good old’ clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur. J. Cancer (2004) 40(12):1837-1841.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, FAZZARI MJ, CHILDS G: Clinical application of molecular profiling in breast cancer. Future Oncol. (2005) 1(4):485-496.
   PubMedGoogle Scholar
• GOLDHIRSCH A, WOOD WC, GELBER RD et al.: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. (2003) 21:3357-3365.
   PubMed Web of Science ®Google Scholar
• EIFEL P, AXELSON JA, COSTA J et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. (2001) 93:979-989.
   PubMed Web of Science ®Google Scholar
• MODLICH O, PRISACK HB, MUNNES M, AUDRETSCH W, BOJAR H: Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J. Transl. Med. (2005) 3:32.
   PubMed Web of Science ®Google Scholar
• IWAO-KOIZUMI K, MATOBA R, UENO N et al.: Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. (2005) 23(3):422-431.
   PubMed Web of Science ®Google Scholar
• HANNEMANN J, OOSTERKAMP HM, BOSCH CA et al.: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. (2005) 23(15):3331-3342.
   PubMed Web of Science ®Google Scholar
• BUCHHOLZ TA, STIVERS DN, STEC J et al.: Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. (2002) 8(6):461-468.
   PubMed Web of Science ®Google Scholar
• SOTIRIOU C, POWLES TJ, DOWSETT M et al.: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. (2002) 4(3):R3.
   PubMed Web of Science ®Google Scholar
• AYERS M, SYMMANS WF, STEC J et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. (2004) 22(12):2284-2293.
   PubMed Web of Science ®Google Scholar
• FOLGUEIRA MA, CARRARO DM, BRENTANI H et al.: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. (2005) 11(20):7434-7443.
   PubMed Web of Science ®Google Scholar
• CHANG JC, WOOTEN EC, TSIMELZON A et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 362(9381):362-369.
   PubMed Web of Science ®Google Scholar
• CHANG JC, WOOTEN EC, TSIMELZON A et al.: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. (2005) 23(6):1169-1177.
   PubMed Web of Science ®Google Scholar
• AHR A, HOLTRICH U, SOLBACH C et al.: Molecular classification of breast cancer patients by gene expression profiling. J. Pathol. (2001) 195(3):312-320.
   PubMed Web of Science ®Google Scholar
• MODLICH O, PRISACK HB, MUNNES M, AUDRETSCH W, BOJAR H: Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin. Cancer Res. (2004) 10(19):6418-6431.
   PubMed Web of Science ®Google Scholar
• RODY A, KARN T, GATJE R et al.: Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl. Gynakol. (2006) 128(2):76-81.
   PubMedGoogle Scholar
• THUERIGEN O, SCHNEEWEISS A, TOEDT G et al.: Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. (2006) 24(12):1839-1845.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF A: European research crisis: the cancer community must make its voice heard. Cancer World (2005) July – August:12-21.
   Google Scholar